Motesanib Diphosphate

Generic Name: AMG 706
Study IDStudied Indication or DiseasePhaseStudy TitleSynopsis
20030242Antiangiogenic therapy of advanced colorectal cancer1bA Phase 1b Open Label Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Oral AMG 706 in Combination with FOLFOX4 as First-Line Therapy in Subjects with Advanced Colorectal Cancer
20040110Second-line monotherapy in subjects with GIST who have received treatment with imatinib mesylate but experienced progressive disease2An Open Label Study of AMG 706 in Subjects with Advanced Gastrointestinal Stromal Tumors (GISTs) who Developed Progressive Disease or Relapsed While on Imatinib Mesylate
20040153Antiangiogenic and anti-EGFr therapy for advanced non-small cell lung carcinoma1bAn open-label, dose-finding study to evaluate the safety and pharmacokinetics of AMG 706 with Carboplatin/Paclitaxel, AMG 706 with Panitumumab and AMG 706 with Panitumumab and Carboplatin/Paclitaxel in the treatment of subjects with advanced non-small cell lung cancer
20040206Advanced cancer1bAn Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Subjects With Advanced Cancer
20040273Treatment of subjects with locally advanced or metastatic thyroid cancer2A Phase 2, Open-label Study of AMG 706 to Treat Subjects with Locally Advanced or Metastatic Thyroid Cancer
20050130Subjects with solid tumors previously treated on a separate Amgen protocol with AMG 7062An Open Label Treatment Extension Study of AMG 706
20050201Unresectable stage IIIB with pericardial or pleural effusion or stage IV or recurrent non-small cell lung cancer (NSCLC).3A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination with Paclitaxel and Carboplatin for Advanced Non-small Cell Lung Cancer
20050225HER2 Negative Locally Recurrent or Metastatic Breast Cancer in Women2A Randomized Phase 2 Trial of Double-blind, Placebo-controlled AMG 706 in Combination With Paclitaxel, or Open-label Bevacizumab in Combination With Paclitaxel as First-line Therapy in Women With HER2 Negative Locally Recurrent or Metastatic Breast Cancer
20060136Treatment of subjects with unresectable stage IIIB with pericardial or pleural effusion or stage IV/recurrent non-squamous non-small cell lung cancer (NSCLC)2A Phase 2, Multicenter, Open Label, Randomized Trial of AMG 706 or Bevacizumab in Combination With Paclitaxel and Carboplatin for Advanced Non-squamous Non-small Cell Lung Cancer
20080639Advanced solid tumours1An Open-label, Single Dose Study of the Mass Balance and Metabolic Disposition of Orally Administered [14C]-labeled AMG 706 (Motesanib) Followed by Extended Treatment with Motesanib in Subjects with Advanced Solid Tumours